Pharmaceutical Product Monograph: Amoxicillin & Clavulanate Potassium Injection
In the pharmaceutical industry, the combination of Amoxicillin and Clavulanate Potassium (often referred to as Co-Amoxiclav) is a broad-spectrum Beta-lactamase inhibitor antibiotic. As a pharmacist and manufacturer, I view this formulation as a “Shielded Penicillin”—it is technically designed to restore the efficacy of Amoxicillin against bacteria that have evolved to produce defensive enzymes.
At your WHO-GMP facility in Mumbai, this injection is a high-volume SKU for Secondary and Tertiary Care settings. It is the gold standard for empirical therapy when a “hidden” or mixed bacterial infection is suspected.
Therapeutic Profile: Primary Indications
Co-Amoxiclav injection is used for the short-term treatment of serious bacterial infections where oral administration is either ineffective or impossible.
| Indication | Clinical Context | Technical Rationale |
| Severe RTI | Pneumonia/Bronchitis | Targets H. influenzae and Moraxella that produce beta-lactamase. |
| Surgical Prophylaxis | Pre-Operative | Used in gastrointestinal, pelvic, or head and neck surgeries to prevent post-op infection. |
| Skin & Soft Tissue | Cellulitis/Abscesses | Effective against Staphylococci and anaerobic bacteria found in bite wounds or diabetic ulcers. |
| Bone & Joint | Osteomyelitis | Provides the high tissue penetration required to treat deep-seated bone infections. |
| Intra-abdominal | Peritonitis | Covers a broad range of gut-related aerobic and anaerobic pathogens. |
Mechanism: The “Shield and Sword” Strategy
This combination works through a dual-action biochemical process:
Amoxicillin (The Sword): It binds to Penicillin-Binding Proteins (PBPs) in the bacterial cell wall, inhibiting the final stage of cross-linking. This causes the cell wall to weaken and burst (osmotic lysis).
Clavulanate Potassium (The Shield): Many bacteria produce an enzyme called Beta-lactamase that “eats” the penicillin molecule before it can work. Clavulanate is a “Suicide Inhibitor”—it binds irreversibly to these enzymes, “distracting” them so the Amoxicillin can successfully attack the bacteria.
The Pharmacist’s “Technical Warning”
The “Penicillin Allergy” Screen: As a pharmacist, I must emphasize that this drug is strictly contraindicated in anyone with a history of anaphylaxis to penicillins or cephalosporins.
Hepatic Monitoring: Co-Amoxiclav is technically associated with a higher risk of Cholestatic Jaundice than Amoxicillin alone. Liver function should be monitored during prolonged courses.
Reconstitution Stability: Once the dry powder is reconstituted with Water for Injections, it is highly unstable. It must be administered within 20 minutes; any remaining solution must be discarded.
Slow IV Injection: It should be administered by slow intravenous injection over 3 to 4 minutes to minimize the risk of vein irritation (thrombophlebitis).
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Moisture-Free” USP: On your digital marketplace, highlight your Aseptic Powder Filling environment. Clavulanate Potassium is extremely hygroscopic (absorbs moisture from the air). Even a trace of humidity during filling can cause the powder to turn brown and lose potency.
The “Twin-Pack” Offering: For international tenders, provide the vial along with a 10 mL or 20 mL Sterile Water for Injection (WFI) ampoule. This “Complete Kit” approach is a major B2B advantage for rural hospital procurement.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for strengths like 600 mg (500/100) and 1.2 g (1000/200) to support your registration in global markets.